Hvis det nå kan heve kursen noen 100% så hadde det vært fint
Ny oversikt lenger nede.
Skulle tro det kommer en “ESMO Biomarker Update” fra BGBIO i morgon bitti.
Syns det er mye bevegelse i toppen til at volumet føles så utrolig lavt i den daglige handelen.
@AndreasP Ja, jeg tror det er tre titler som inneholder en referanse til bemcentinib.
En på biomarkør, en på melanom og en på MDS og AXL. Har så store forventninger her så hadde jo vært moro og blitt positivt overrasket
1266P - Update on the randomised Phase Ib/II study of the selective small
molecule AXL inhibitor bemcentinib (BGB324) in combination with either
dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
1009PD - The identification of the AXL/Gas6 signalling axis as a key player of
myelodysplastic syndrome (MDS) and the potential of the oral selective AXL
inhibitor bemcentinib in the treatment of MDS
63PD - Predictive and Pharmacodynamic Biomarkers Associated with Phase II,
selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple
Er forresten usikker på om vi får abstract fra de to andre i natt. Lurer på om suffixen PD etter tallene står for poster discussion, hvorpå det ikke blir frigitt før 19. oktober (tror jeg).
Veldig liten float i aksjen.
Jeg finner de to som er poster discussion, men de har ikke tilgjengelig abstract enda.
For den på melanom så finne jeg ingenting: https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar?
Fant til slutt
Upregulation of the receptor tyrosine kinase AXL has been linked with both minor treatment effect of PD-1 blockade and acquired resistance to BRAF inhibitors in melanoma. Bemcentinib is a first-in-class orally bioavailable selective inhibitor of AXL which is currently investigated in several phase II clinical trials. BGBIL006 (NCT02872259) is an open label phase Ib/II trial designed to explore whether combination with bemcentinib improves overall response rates to standard of care therapies in patients (pts) with metastatic melanoma (MM).
Dose escalation of bemcentinib in combination with 150mg twice daily/2mg daily dabrafenib/trametinib (D/T) in newly diagnosed, BRAF+, MM with high tumour load followed a 3 + 3 design (part 1). In part 2, pts were randomised 2:1 to receive D/T or pembro +/- bemcentinib at RP2D, respectively, based on mutation status and tumour load. Pts were allowed to switch D/T with pembrolizumab and vice versa upon progression (part 3). Tumour responses were assessed per investigator using RECIST v1.1. Plasma protein biomarker levels were measured using the DiscoveryMap v3.3 panel (Myriad RBM) in pts pre-dose and at C2D1.
In part 1, 6 pts were enrolled first line (age 34-71, LDH > 1 x ULN 50%). There was 1 dose limiting toxicity (G3 rash) and an RP2D of bemcentinib in combination with D/T of 200mg daily bemcentinib with full dose D/T was confirmed. As of 2 May 18, a further 17 pts have been enrolled into part 2 of the study and four had progressed to part 3. Grade 3 treatment-related adverse events (AEs) were observed in 7 pts (30%). No G4 AEs or treatment related deaths occurred. Biomarkers candidates predicting treatment benefit were explored. Pre/post treatment changes of soluble proteins will be presented.
Bemcentinib RP2D (200 mg daily) is well tolerated in combination with both D/T and pembro without increased toxicity compared to either therapeutic approach alone. Further investigation of safety and efficacy as well as biomarker candidates is ongoing.
You rock man🤘
BerGenBio to present interim phase II clinical, preclinical and biomarker data with selective AXL inhibitor bemcentinib at ESMO
Bergen, Norway, 9 October 2018 - BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical and biomarker data from its Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor at the ESMO 2018 Congress in Munich (19 - 23 October 2018).
Pre-clinical data on the role of AXL inhibition in Myelodysplastic Syndrome (MDS) will also be presented. Details of the presentations are below.
The posters will be made available at www.bergenbio.com in the Investors / Presentations section at the time of presentation and full abstracts will be made available online according to ESMO’s embargo schedule: https://www.esmo.org/Conferences/ESMO-2018-Congress/Abstracts
Poster presentations at ESMO:
Sunday 21 October, 11:15 - 12:15, Hall B3 - Room 21
Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials
· Robert Holt, PhD et al
· Poster Discussion session - Translational research 2
· Invited discussant: 11:15 - 11:45
· Presentation number: 63PD
Sunday 21 October, 12:45 - 13:45, Hall A3 - Poster Area
Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
· Cornelia Schuster, MD, PhD et al
· Poster display session - Melanoma and other skin tumours
· Presentation number: 1266P
Sunday 21 October, 16:30 - 17:45, Hall B3 - Room 21
The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS
· Hind Medyouf, PhD et al
· Poster Discussion session - Haematological malignancies
· Invited discussant: 16:30 - 16:55
· Presentation number: 1009PD
- END -
About the ESMO Congress
The ESMO Congress is the leading European meeting for medical oncology convening over 20,000 international delegates from the field. ESMO 2018 will be held in Munich, Germany 19- 23 October 2018.
About BerGenBio’s Companion Diagnostics programme
In parallel with its phase II clinical trial programme, BerGenBio explores predictive biomarker candidates with the aim to develop a companion diagnostic to identify patients most likely to benefit from bemcentinib treatment.
Thus far, the company reported strong correlation with response of both plasma soluble AXL levels and the presence of tissue AXL in relapsed/refractory AML or MDS and advanced NSCLC, respectively.
About the BGBIL006 trial
Melanoma is the most serious type of skin cancer as it may spread to lymph nodes and distant organs if not discovered in time. Melanoma occurs when the cells that colour the skin, the so-called melanocytes, start to divide uncontrollably.
The BGBIL006 trial is a randomised Phase 1b/2 investigator sponsored clinical study of bemcentinib (BGB324) in combination with either the MAPK inhibitors MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or the immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.
For more information please access trial NCT02872259at www.clinicaltrials.gov.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent.
In parallel, BerGenBio is developing a companion diagnostics test to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials and support a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL drives tumour survival, treatment resistance and spread, as well as suppressing the body’s immune response to tumours. AXL expression has been established as a negative prognostic factor in many cancers. AXL inhibitors, therefore, have potential value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities.
CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
+44 207 638 9571
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Nyheten er levert av Cision.
Oppdatert info om BerGEnBio fra Trinity Delta:
Drar ut dette utdraget da det er spennende med tanke på oppstart av nye studier (det snakkes om de to nye investigator sponsede studiene):
“These two new trials demonstrate the interest in Axl inhibition and in
bemcentinib, the first-in-class selective Axl inhibitor. This interest is likely to
continue to grow on the back of the updated data from the three Phase II studies
in non-small cell lung cancer (NSCLC) that has just been presented at the World
Conference on Lung Cancer (WCLC).”
Konservativt, men ikke akkurat uventet at analytikere avventer med å øke kursmålet ytterligere…
Direktelink til oppdatert analyse:
(Fra siden @Larsmkn postet over)
Ja, jeg tenker de uansett vil vente til de nye studiene har startet opp og TNBC studien er fjernet. Blir sikkert nytt kursmål ut i nyåret.
Har plukket ut de 11 heteste oppkjøpskandidatene
ABG Sundal Collier spår tror det kan komme en oppkjøpsbølge i Norge og Norden, og har i en fersk analyse listet opp de 11 heteste kandidatene på Oslo Børs, skriver Finansavisen:
For hele Norden trekkes helse, IT og finans frem som de mest attraktive sektorene.
Av faktorer meglerhuset har lagt til grunn trekker analysesjef Christer Lindé frem geografisk footprint, attraktiv teknologistruktur og skalafordeler.
Meglerhuset trekker frem at Norden er spesielt godt rigget for oppkjøp med bakgrunn i gode offentlige finanser, bra demografi og global eksponering.
42000 post salg på 33 kr for en oppkjøpskandidat!
Dette er rett og slett å sette bremse og plukke billige aksjer/stopplosse poster før snarlig oppgang! Please fasten your Seat belts $$$
Takk for grundige og gode oversikter. Tok et lodd her på 32,50 da kursen har falt med ca 40% fra årets høyeste (54,80), og da det fundamentale ser bra ut. Teknisk ser den litt svak ut, men det tror jeg ikke man skal legge for stor vekt på
Jeg har veldig tro på dette selskapet selv så håper det viser seg å være et lønnsomt lodd fra din side
Ja, volumet på denne aksjen er ikke all verdens, og jeg antar at det gjør tekniske vurderinger mer usikkre?
Var i bryllup m CSO i helgen, men han var taus som en østers
Du kjørte ikke det gamle whisky-trikset?
Untouchable. Kanskje Bourbon da han er amerikaner?